Natco Pharma Ltd on Friday reported a 57 per cent decline in consolidated net profit at Rs 206.5 crore in the first quarter ended June 2026, hit by lower sales of its generic cancer treatment drug lenalidomide.
The company had posted a consolidated net profit of Rs 480.3 crore in the corresponding quarter last fiscal, Natco Pharma said in a regulatory filing.
Consolidated revenue from operations in the first quarter was lower at Rs 735.2 crore in the first quarter as compared to Rs 1,328.9 crore in the corresponding period a year ago, it added.
The decline is largely attributable to lower lenalidomide revenue in the current quarter, which was partially offset by growth in the base business, the company said.
Total expenses in the quarter under review were lower at Rs 608.8 crore as compared to Rs 818.7 crore in the same period a year ago, it added.
In the first quarter, domestic pharmaceutical formulations revenue was at Rs 136.4 crore, up from Rs 107 crore in the year-ago period.
On the other hand, international formulations had a lower revenue of Rs 477.1 crore as against Rs 1,120.9 crore in the corresponding quarter last fiscal, Natco Pharma said.
Active pharmaceutical ingredients (API) segment clocked revenue of Rs 66.7 crore in the first quarter as compared to Rs 52.6 crore in the same period last fiscal, it added.
